On June 17, 2021 Anji Pharma ("Anji"), a global pharmaceutical company focused on tackling high-value drug targets validated by human genetics, reported that an Anji subsidiary has acquired worldwide development and commercialization rights to an MCL1 inhibitor program through a license from the Broad Institute of MIT and Harvard and will work to advance the program’s MCL1 inhibitors through clinical development (Press release, Anji Pharmaceuticals, JUN 17, 2021, View Source [SID1234584173]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

MCL1 is a member of the Bcl-2 family, normally acting as a "brake" on the apoptosis pathway. In many human cancers, the Mcl-1 gene is highly amplified, shifting the balance from pro- to anti-apoptotic signals and promoting cancer cell survival and tumor formation. Molecules which selectively block MCL1 function induce rapid and specific killing of cancer cells in preclinical models when administered as single agent or in combination with other targeted therapy.

"MCL1 has always been at the top of our list for oncology mechanisms, given its pronounced amplification across tumor types and central role in orchestrating chemotherapy resistance," noted Dan Meyers, M.D., Chief Medical Officer of Anji. "We believe this specific class of MCL1 inhibitors has a unique profile that could offer a wider safety window and better outcomes for cancer patients."

"Our interest in this MCL1 program reaffirms our commitment to pursue compelling mechanisms – regardless of disease indication – and develop therapies that can help patients across the globe," added Brian Hubbard, Ph.D., Chief Executive Officer of Anji. "What matters to us most is whether it will work, and then we commit our clinical and regulatory experience to bring treatments to patients as safely and quickly as possible."

The MCL1 program is one of several programs pursued by the Center for Development of Therapeutics (CDoT) at the Broad Institute. CDoT is a highly collaborative team of professional scientists who work closely with Broad’s principal investigators to advance deep biological insights into therapeutics.